Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment.

Autor: Chelushkin MA; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van Dorp J; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Wilpe S; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Seignette IM; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Mellema JJ; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Alkemade M; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., Gil-Jimenez A; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Peters D; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., Brugman W; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands., Stockem CF; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hooijberg E; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Rhijn BWG; Department of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Mertens LS; Department of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Heijden AG; Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands., Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., van Montfoort ML; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Wessels LFA; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, the Netherlands., Vis DJ; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van der Heijden MS; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 13; Vol. 30 (18), pp. 4227-4239.

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

Autor: van Dorp J; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands., Pipinikas C; Inivata Ltd., Babraham Research Park, Cambridge, UK., Suelmann BBM; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Mehra N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., van Dijk N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Marsico G; Inivata Ltd., Babraham Research Park, Cambridge, UK., van Montfoort ML; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hackinger S; Inivata Ltd., Babraham Research Park, Cambridge, UK., Braaf LM; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Amarante T; Inivata Ltd., Babraham Research Park, Cambridge, UK., van Steenis C; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands., McLay K; Inivata Ltd., Babraham Research Park, Cambridge, UK., Daletzakis A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Kamp MW; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., Hendricksen K; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., de Feijter JM; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boellaard TN; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Meijer RP; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urological Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Heijden AG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Rosenfeld N; Inivata Ltd., Babraham Research Park, Cambridge, UK.; Cancer Research UK Cambridge Institute, Cambridge, UK.; Cancer Research UK Major Centre Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK., van Rhijn BWG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany., Jones G; Inivata Ltd., Babraham Research Park, Cambridge, UK. greg.jones@inivata.com., van der Heijden MS; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands. ms.vd.heijden@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ms.vd.heijden@nki.nl.

Publikováno v: Nature medicine [Nat Med] 2024 Jan; Vol. 30 (1), pp. 304.

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

Autor: van Dorp J; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands., Pipinikas C; Inivata Ltd., Babraham Research Park, Cambridge, UK., Suelmann BBM; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Mehra N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., van Dijk N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Marsico G; Inivata Ltd., Babraham Research Park, Cambridge, UK., van Montfoort ML; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hackinger S; Inivata Ltd., Babraham Research Park, Cambridge, UK., Braaf LM; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Amarante T; Inivata Ltd., Babraham Research Park, Cambridge, UK., van Steenis C; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands., McLay K; Inivata Ltd., Babraham Research Park, Cambridge, UK., Daletzakis A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Kamp MW; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., Hendricksen K; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., de Feijter JM; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boellaard TN; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Meijer RP; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urological Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Heijden AG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Rosenfeld N; Inivata Ltd., Babraham Research Park, Cambridge, UK.; Cancer Research UK Cambridge Institute, Cambridge, UK.; Cancer Research UK Major Centre Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK., van Rhijn BWG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany., Jones G; Inivata Ltd., Babraham Research Park, Cambridge, UK. greg.jones@inivata.com., van der Heijden MS; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands. ms.vd.heijden@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ms.vd.heijden@nki.nl.

Publikováno v: Nature medicine [Nat Med] 2023 Mar; Vol. 29 (3), pp. 588-592. Date of Electronic Publication: 2023 Feb 02.

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.

Autor: van Dorp J; Department of Molecular Carcinogenesis, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Montfoort ML; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Dijk N; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., de Feijter JM; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Bergman AM; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Hendricksen K; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van der Poel HG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Rhijn BWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany., van der Heijden MS; Department of Molecular Carcinogenesis, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: ms.vd.heijden@nki.nl.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2022 Apr; Vol. 20 (2), pp. e173-e179. Date of Electronic Publication: 2021 Dec 10.

The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.

Autor: van Dijk N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Gil-Jimenez A; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Silina K; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., van Montfoort ML; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Einerhand S; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Jonkman L; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, Netherlands., Voskuilen CS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Peters D; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, Netherlands., Sanders J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Lubeck Y; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, Netherlands., Hooijberg E; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Vis DJ; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., van den Broek M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Wessels LFA; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands.; Department of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, Netherlands., van Rhijn BWG; Department of Urology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany., van der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Publikováno v: Frontiers in immunology [Front Immunol] 2021 Dec 20; Vol. 12, pp. 793964. Date of Electronic Publication: 2021 Dec 20 (Print Publication: 2021).